HMG-CoA reductase inhibitors

被引：0
作者：
不详
机构：
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 1996年 / 6卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：77 / 78
页数：2
相关论文
共 5 条
[1]   REDUCTION IN SERUM-CHOLESTEROL WITH PRAVASTATIN IMPROVES ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA [J].
EGASHIRA, K ;
HIROOKA, Y ;
KAI, H ;
SUGIMACHI, M ;
SUZUKI, S ;
INOU, T ;
TAKESHITA, A .
CIRCULATION, 1994, 89 (06) :2519-2524
[2]   TISSUE SELECTIVITY OF PRAVASTATIN SODIUM, LOVASTATIN AND SIMVASTATIN - THE RELATIONSHIP BETWEEN INHIBITION OF DENOVO STEROL SYNTHESIS AND ACTIVE-DRUG CONCENTRATIONS IN THE LIVER, SPLEEN AND TESTIS IN RAT [J].
KOGA, T ;
FUKUDA, K ;
SHIMADA, Y ;
FUKAMI, M ;
KOIKE, H ;
TSUJITA, Y .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 209 (01) :315-319
[3]   BENEFICIAL EFFECT OF CHOLESTEROL-LOWERING THERAPY ON CORONARY ENDOTHELIUM-DEPENDENT RELAXATION IN HYPERCHOLESTEROLEMIC PATIENTS [J].
LEUNG, WH ;
LAU, CP ;
WONG, CK .
LANCET, 1993, 341 (8859) :1496-1500
[4]  
LIJUAN M, 1994, BIOCHEM BIOPH RES CO, V203, P1355
[5]   THE PATHOGENESIS OF ATHEROSCLEROSIS - A PERSPECTIVE FOR THE 1990S [J].
ROSS, R .
NATURE, 1993, 362 (6423) :801-809
1